NIAID-Led Study of mRNA Vaccine Supports Advance to Phase 3 Human Trials
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts. The animal study results published online today in the New England Journal of Medicine complement recently reported interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273. The candidate mRNA-1273 vaccine is manufactured by Moderna.
In this study, three groups of eight rhesus macaques received two injections of 10 or 100 micrograms (µg) of mRNA-1273 or a placebo. Injections were spaced 28 days apart. Vaccinated macaques produced high levels of neutralizing antibodies directed at the surface spike protein used by SARS-CoV-2 to attach to and enter cells. Notably, say the investigators, animals receiving the 10-µg or 100-µg dose vaccine candidate produced neutralizing antibodies in the blood at levels well above those found in people who recovered from COVID-19.
The experimental vaccine also induced Th1 T-cell responses but not Th2 responses. Induction of Th2 responses has been associated with a phenomenon called vaccine-associated enhancement of respiratory disease (VAERD). Vaccine-induced Th1 responses have not been associated with VAERD for other respiratory diseases. In addition, the experimental vaccine induced T follicular helper T-cell responses that may have contributed to the robust antibody response.
Four weeks after the second injection, all the macaques were exposed to SARS-CoV-2 via both the nose and the lungs. Remarkably, after two days, no replicating virus was detectable in the lungs of seven out of eight of the macaques in both vaccinated groups, while all eight placebo-injected animals continued to have replicating virus in the lung. Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure. This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. A COVID-19 vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially lessen transmission of SARS-CoV-2 and consequently reduce the spread of disease, they add.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippineson March 6, 2021 at 2:23 pm
Moderna announces supply agreement to provide 13 million doses of COVID-19 Vaccine Moderna to the Philippines.
- The vaccine revolution is coming inside tiny bubbles of faton March 6, 2021 at 12:49 pm
Lipids catapulted toward the top of the world's health-care priority list because the potent vaccines from Pfizer-BioNTech and Moderna, as well as others still being developed by CureVac and Sanofi, c ...
- Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?on March 5, 2021 at 3:29 pm
I shot the attached video on Wednesday recommending buys of both Moderna MRNA and Novavax NVAX -- right before the correction in growth stocks got rolling downhill fast! The good news is that Moderna ...
- How mRNA vaccines workon March 5, 2021 at 1:17 pm
Scientists who contributed to Moderna's vaccine explain scientific breakthroughs and how previous studies on viruses gave them an edge ...
- Should You Be Concerned About mRNA COVID Vaccines?on March 4, 2021 at 5:31 am
Two of the COVID-19 vaccines that have received U.S. emergency use authorization (EUA) use messenger RNA (mRNA) technology. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) became the first companies to ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Why Moderna Was a Roller Coaster Todayon March 5, 2021 at 5:11 pm
Moderna (NASDAQ:MRNA) provided an up-and-down ride for its investors on Friday, with the stock trading as much as 1.5% higher and 8.5% lower than its previous day's close. Ultimately, it landed ...
- Takeda Submits NDA To Import And Distribute Moderna's COVID-19 Vaccine Candidate In Japanon March 4, 2021 at 10:42 pm
(MRNA) said Friday that Takeda Pharmaceutical Co., Ltd (TAK) submitted a New Drug Application to the Government of Japan's Ministry of Health, Labour and Welfare or MHLW to import and distribute ...
- Moderna Announces New Drug Application Submitted to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japanon March 4, 2021 at 2:30 pm
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Takeda Pharmaceutical Co., Ltd (NYSE: TAK) submitted a New Drug ...
- Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Studyon February 26, 2021 at 8:55 pm
While initial data confirms that the Moderna COVID-19 Vaccine (mRNA-1273) provides neutralizing activity against variants of concern, out of an abundance of caution, Moderna is pursuing two strategies ...
- Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Studyon February 25, 2021 at 1:45 pm
While initial data confirms that the Moderna COVID-19 Vaccine (mRNA-1273) provides neutralizing activity against variants of concern, out of an abundance of caution, Moderna is pursuing two ...